# Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs Canonical URL: https://biopharmsignal.com/news/JAGX/jaguar-health-announces-statistically-significant-results-from-effectiveness-trial-of-crofelemer-fda-approved-canalevia-ca1-for-treatment-of-chemotherapy-induced-diarrhea-in-dogs Ticker: JAGX Company: Jaguar Health Source: Jaguar Health Published: 2026-04-29 12:30 EST Original Source URL: https://jaguarhealth.gcs-web.com ## Summary Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc.   (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of its effectiveness trial of crofelemer (FDA ## Article Body Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of its effectiveness trial of crofelemer (FDA ## Recent Company News - 2026-05-28 14:00 EST — [Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders](https://biopharmsignal.com/news/JAGX/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetically-defined-rare-congenital-gastrointestinal-disorders) — Source: Jaguar Health - 2026-05-27 13:00 EST — [Jaguar Health Compliant with Nasdaq Bid Price Rule](https://biopharmsignal.com/news/JAGX/jaguar-health-compliant-with-nasdaq-bid-price-rule) — Source: Jaguar Health - 2026-05-20 20:40 EST — [Jaguar Health Reports First Quarter 2026 Financials](https://biopharmsignal.com/news/JAGX/jaguar-health-reports-first-quarter-2026-financials) — Source: Jaguar Health - 2026-05-20 13:00 EST — [Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference](https://biopharmsignal.com/news/JAGX/jaguar-health-to-hold-investor-webcast-may-26-regarding-q1-2026-financials-and-corporate-updates-jaguar-ceo-lisa-conte-presenting-may-28-at-lytham-partners-spring-2026-investor-conference) — Source: Jaguar Health - 2026-05-19 13:00 EST — [Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-active-treatment-only-continuation-of-pivotal-multicenter-clinical-trial-in-pediatric-patients-with-microvillus-inclusion-disease-mvid-to-support-a-new-drug-application-nda-for-liquid-oral-crofelemer) — Source: Jaguar Health ## Related News - 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522) - 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043) - 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)